RT Journal Article
SR Electronic
T1 Alternative Approaches for Modelling COVID-19: High-Accuracy Low-Data Predictions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.22.20159731
DO 10.1101/2020.07.22.20159731
A1 Dewang Kumar Agarwal
A1 Soham De
A1 Ojas Shukla
A1 Archit Checker
A1 Apoorvi Mittal
A1 Ankita Borah
A1 Debayan Gupta
YR 2020
UL http://medrxiv.org/content/early/2020/07/25/2020.07.22.20159731.abstract
AB Background Numerous models have tried to predict the spread of COVID-19. Many involve myriad assumptions and parameters which cannot be reliably calculated under current conditions. We describe machine-learning and curve-fitting based models using fewer assumptions and readily available data.Methods Instead of relying on highly parameterized models, we design and train multiple neural networks with data on a national and state level, from 9 COVID-19 affected countries, including Indian and US states and territories. Further, we use an array of curve-fitting techniques on government-reported numbers of COVID-19 infections and deaths, separately projecting and collating curves from multiple regions across the globe, at multiple levels of granularity, combining heavily-localized extrapolations to create accurate national predictions.Findings We achieve an R2 of 0·999 on average through the use of curve-fits and fine-tuned statistical learning methods on historical, global data. Using neural network implementations, we consistently predict the number of reported cases in 9 geographically- and demographically-varied countries and states with an accuracy of 99·53% for 14 days of forecast and 99·1% for 24 days of forecast.Interpretation We have shown that curve-fitting and machine-learning methods applied on reported COVID-19 data almost perfectly reproduce the results of far more complex and data-intensive epidemiological models. Using our methods, several other parameters may be established, such as the average detection rate of COVID-19. As an example, we find that the detection rate of cases in India (even with our most lenient estimates) is 2.38% - almost a fourth of the world average of 9% [1].Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere was no external funding provided for this study and the authors used personal resources to carry out this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe corresponding author confirms that he had full access to all data in this study and had final responsibility for submitting this manuscript for publication. All data has been taken from publicly available repositories. All the code used in the manuscript is provided in a public repository. https://ourworldindata.org/coronavirus https://github.com/nytimes/covid-19-data https://api.covid19india.org/csv/latest/raw_data.csv https://github.com/debayanLab/covidPredictions